The Ohio State University Wexner Medical Center is part of a nationwide consortium created to address research gaps related to important relationships between pancreatic cancer and chronic pancreatitis. The Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer comprises 10 centers and is funded by the National Institute for Diabetes and Digestive and Kidney Diseases and National Cancer Institute.
Phil Hart, MD, a gastroenterologist at Ohio State Wexner Medical Center, has been an integral member of the consortium from the start and is leading a study to investigate diabetes mellitus secondary to pancreatic cancer and chronic pancreatitis. The goal is to discover and validate a method to differentiate these two subtypes of diabetes from the more common type 2 diabetes. Diabetes is the first sign of pancreatic cancer for many patients, so this test would permit more opportunity for early detection and improved survival.
The multicenter study, titled “Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis” (DETECT study for short), will examine differences in pancreatic and gut hormones as well as glucose excursion following a mixed meal test. If the results are promising, this test can easily be performed at any hospital or clinic. The study is enrolling at the participating centers, and Dr. Hart anticipates performing the first interim analysis in summer 2019.